Sangamo Cleared by FDA to Begin First Gene Editing Clinical Trial

Dec 4, 2015, 13:33 by Michael Croft

New Scientist | Sangamo BioSciences' gene editing therapy for hemophilia B, based on zinc finger nuclease technology, can go forward in the first study of such a therapy in humans.

December 04, 2015 | Sangamo BioSciences' gene editing therapy for hemophilia B, based on zinc finger nuclease technology, can go forward in the first study of such a therapy in humans. New Scientist